Hudson Bay Capital Management
FBRX

Hudson Bay Capital Management’s Forte Biosciences FBRX Stock Holding History

Hudson Bay Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,083
Closed -$494K – 1455
2026
Q1 		$494K Buy
19,083
+2,541
+15% +$73.2K ﹤0.01% 981
2025
Q4 		$451K Buy
+16,542
New +$290K ﹤0.01% 886

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Hudson Bay Capital Management's FBRX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Forte Biosciences (FBRX) in Q2 2026, closing a stake of 19,083 shares — an estimated $494K sold.

Hudson Bay Capital Management first reported a position in FBRX in Q4 2025 and held it in 2 quarters. The position peaked at $494K in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Forte Biosciences position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 19,083 Forte Biosciences shares in Q2 2026, an estimated $494K.
  • Hudson Bay Capital Management first reported a position in Forte Biosciences in Q4 2025 and held it in 2 quarters.
  • Hudson Bay Capital Management's Forte Biosciences position peaked at $494K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.